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Abstract
Myocardial remodeling and heart failure (HF) are common sequelae of many forms of cardiovascular disease and a leading
cause of mortality worldwide. Accumulation of damaged cardiac proteins in heart failure has been described. However, how
protein quality control (PQC) is regulated and its contribution to HF development are not known. Here, we describe a novel
role for activated protein kinase C isoform bII (PKCbII) in disrupting PQC. We show that active PKCbII directly phosphorylated
the proteasome and inhibited proteasomal activity in vitro and in cultured neonatal cardiomyocytes. Importantly, inhibition
of PKCbII, using a selective PKCbII peptide inhibitor (bIIV5-3), improved proteasomal activity and conferred protection in
cultured neonatal cardiomyocytes. We also show that sustained inhibition of PKCbII increased proteasomal activity,
decreased accumulation of damaged and misfolded proteins and increased animal survival in two rat models of HF.
Interestingly, bIIV5-3-mediated protection was blunted by sustained proteasomal inhibition in HF. Finally, increased cardiac
PKCbII activity and accumulation of misfolded proteins associated with decreased proteasomal function were found also in
remodeled and failing human hearts, indicating a potential clinical relevance of our findings. Together, our data highlights
PKCbII as a novel inhibitor of proteasomal function. PQC disruption by increased PKCbII activity in vivo appears to contribute
to the pathophysiology of heart failure, suggesting that PKCbII inhibition may benefit patients with heart failure. (218
words)
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Introduction
Maintenance of blood circulation during continual stress, such
as hypertension or following cardiac ischemic events and
infarction, contributes to cardiac wear and tear and results in
accumulation of damaged cardiac proteins leading to cell death
and further deterioration of cardiac functions. The cellular protein
quality control (PQC) can detect, repair and dispose of cytotoxic
damaged proteins using multiple control mechanisms, which
include chaperone proteins, the ubiquitin-proteasome system
(UPS) and autophagy [1]. The UPS is the primary effector of
the PQC process, protecting long-lived cells, such as neurons and
cardiomyocytes, from accumulation of aberrant and misfolded
proteins [2]. The pathophysiological role of the PQC machinery in
the heart emerged from studies showing accumulation of damaged
proteins in humans and in animal models with cardiac diseases as
well as cardiac mutations in PQC components [3,4]. There is also
up-regulation of proteins involved in UPS and elevated levels of
ubiquitinated proteins in hearts of human dilated cardiomyopathy
[5]. Some studies found an overall decrease in proteasomal activity
associated with and probably contributing to the increased steady
state level of ubiquitinated proteins and cell death [5,6]. However,
others reported that several components of the ubiquitin-protein
system and/or its overall activity are increased in experimental
compensated cardiac hypertrophy and heart failure [7]. There-
fore, it remains to be determined whether dysfunction of specific
PQC components, such as the UPS, contribute to the develop-
ment of end-stage heart failure and which signaling events regulate
them.
Numerous studies have focused on identifying intracellular
nodes where signals converge and serve as multi-effector brakes to
suppress or reverse heart failure. We and others have identified
PKCbII, which is over activated in failing hearts of humans [8]
and in animal models [8,9,10,11], as a potential key player in heart
failure. However, the molecular targets of PKCbII are still
unknown.
Using human remodeled and failing hearts with different
etiologies and two different heart failure models in rats (myocardial
infarction-induced and hypertension-induced heart failure; HF),
we found a pronounced decline in components of the PQC
machinery. Furthermore, we show for the first time that PKCbII,
which is over-activated in HF both in humans [8] and in animal
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33175models [12,13], disturbed cardiac PQC by decreasing proteasomal
activity. Using different PKC-selective regulators [14], we then
demonstrated here that the PKCbII-specific peptide inhibitor,
bIIV5-3, prevented the decline in PQC in cultured neonatal
cardiac myocytes and that sustained PKCbII inhibition substan-
tially increased survival and cardiac function in myocardial
infarction-induced and hypertension-induced heart failure animal
models in rats. The molecular bases of these events were also
studied.
Results
PQC dysfunction parallels heart failure development in
an animal model
To investigate whether injury-induced progression to heart
failure is associated with PQC dysfunction, we evaluated
proteasomal activity and accumulation of damaged cardiac
proteins in a rat model of myocardial infarction-induced heart
failure (Fig. 1A). All measurements were performed in a region
remote from the infarcted area in the left ventricle (non-infarcted
zone). We found a progressive decline in proteasomal activity
during 10 weeks following myocardial infarction that exhibited a
tight correlation with the decline in cardiac function (R
2=0.61,
p=0.0001; Fig. 1B, E, F and H), reaching a deficit of 68% and
66%, respectively, when compared with sham-operated rats. The
decreased proteasomal activity correlated with an increased
accumulation of cardiac oxidized proteins and soluble oligomers
of misfolded proteins in the failing hearts (R
2=0.81, p=0.0001,
Fig. 1C, D, G and H). Similar to results observed in human HF
hearts [8,15], we found that, of the PKC isozymes present in rat
heart, only PKCbII was activated in the myocardial infarction-
induced failed hearts, as evidenced by its increased association
with the cell particulate fraction (Fig. 1I); there was also a 3-fold
increase in catalytic activity of PKCbII, as compared with that
from control rat hearts (Fig. 1J).
PKCbII activation directly down-regulates proteasomal
activity
We next determined whether PKCbII directly regulates
proteasomal activity. Active PKCbII (but not aPKC or PKCbI)
phosphorylated and decreased the proteolytic function of the
purified 20S proteasome by 55%, in vitro (Fig. 2A, bottom and top
panel, respectively). PKCbII activation-mediated proteasomal
phosphorylation was essential to decreased proteasomal activity,
since inactive PKCbII (added in the absence of its activators, PS/
DG/Ca
+2) had no effect on proteasomal function (Fig. 2A).
Further, treatment of cultured neonatal cardiomyocytes with
10 nM phorbol ester 12-myristate 13-acetate (PMA, an activator
of most PKC isozymes) for 30 min induced oxidized protein
accumulation, at least in part, by decreasing the 26S proteasomal
ATP-dependent proteolytic activity (40% decrease) (Fig. 2B).
Using selective peptide inhibitors for PKC isozymes, we found that
only bIIV5-3, a PKCbII-specific peptide inhibitor [14,16,17],
[and not selective inhibitors for a, bI or PKCe (aV5-3 and bIV5-3
and eV1-2, respectively), which are also present in cardiac
myocytes; [18,19]] prevented this PMA-induced proteasomal
inhibition and increased accumulation of damaged proteins
(Fig. 2B). Confirming the pharmacological effect of bIIV5-3,
PKCb knockdown using siRNA similarly abrogated PMA-induced
proteasomal inhibition and oxidized protein accumulation in
neonatal cardiomyocytes (Fig. 2C). In contrast, PKCa knockdown
did not restore PMA-induced proteasomal activity unless cells
were pre-treated also with bIIV5-3 peptide (Fig. 2C). In addition,
bIIV5-3 treatment prevented damaged protein accumulation and
diminished cell death in hydrogen peroxide-treated neonatal
cardiomyocytes (Fig. S1) and epoxomicin (a selective proteasome
inhibitor) abrogated the cytoprotective effect of bIIV5-3.
Sustained PKCbII inhibition and cardiac PQC in the
myocardial infarction-induced heart failure model
To evaluate the effect of PKCbII on cardiac PQC in heart
failure, we further determined whether sustained administration of
bIIV5-3 in a myocardial infarction-induced heart failure model in
rats (Fig. 3A) affected cardiac PQC, cardiac function and survival.
PKCbII (but not PKCe, an abundant isozyme in the heart) co-
immunoprecipitated with the proteasome and decreased its
activity in these failing hearts (Fig. 3B and C). After the
establishment of HF (4 weeks after myocardial infarction; MI), a
subsequent six-week treatment with bIIV5-3 abolished the
increased cardiac PKCbII translocation and activity (Fig. 3A),
but not the activity of a, bI, d, c and PKCe (Fig. S2), and
diminished the co-immunoprecipitation of PKCbII and the 20S
proteasome as well as its phosphorylation (Fig. 3B). This bIIV5-3
treatment resulted also in a two-fold increase in both ATP-
dependent (26S) and -independent (20S) cardiac proteasomal
activity back to control levels (Fig. 3C). There were no changes in
the protein levels of cardiac proteasome subunits in failing hearts
regardless of the treatment (Fig. 3D and Fig. S3). However,
sustained PKCbII inhibition completely suppressed the accumu-
lation of cardiac oxidized proteins, polyubiquitinated proteins and
soluble oligomers of misfolded proteins in these rat samples
(Fig. 3E–G). The increased abnormal protein accumulation in
failed non-treated hearts was accompanied by an ,50% increase
in the levels of the small chaperones, a-b-crystallin and HSP27,
and a two-fold increase in caspase 3 activation, effects that were
reversed by the sustained PKCbII inhibition (Fig. 3D and Fig. S3).
In addition, chronic PKCbII inhibition abolished the HF-induced
increase in the levels of well-known proteasome substrates, IkB and
p53 (Fig. S3).
Importantly, a six-week treatment with bIIV5-3 of animals with
HF resulted in a significant increase of fractional shortening
compared to non-treated heart failure animals (2762 vs. 1462%,
respectively; Fig. 3H). bIIV5-3 treatment also decreased left
ventricular end-diastolic diameter compared to non-treated heart
failure animals (8.560.3 vs. 10.260.2 mm, respectively). The
improved cardiac function following bIIV5-3 treatment (from
19% before treatment to 27% after 6 weeks of bIIV5-3 treatment)
was likely due to improved integrity of cardiac myofibril structure
in the treated hearts, as evidenced by electron microscopy
(Fig. 4A). Improved integrity of cellular structures was also found
in bIIV5-3-treated rats relative to non-treated heart failure
animals (Fig. 4A arrows). Finally, PKCbII inhibition strikingly
improved HF animal survival, whereas sustained bortezomib
treatment (a proteasome inhibitor) abrogated bIIV5-3 therapy-
mediated survival improvement in HF rats and accelerated death
in rats with HF (Fig. 4B–C), but not in control rats (none of the
control animals died after chronic treatment with bortezomib).
Further, bortezomib-treated HF rats did not present any sign of
drug toxicity, based on anatomopathological analysis. The
increased mortality rate of rats with HF in the presence of a
proteasome inhibitor, together with our in vitro and cell culture
experiments, further support our hypothesis that PKCbII
inhibition-associated improvements in heart function/survival is
mediated, at least in part, by better proteasomal function.
PKCbII Inhibition in Heart Failure
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hypertension-induced heart failure model
We next determined whether the role of PKCbII and PQC in
heart failure is independent of the etiology of HF, using a
hypertension-induced heart failure model in Dahl salt-sensitive
rats (Fig. 5A). When placed on a high-salt diet from the age of 6
weeks, Dahl rats exhibit high blood pressure (230 vs. 160 mmHg),
as previously reported [13]. These hypertensive rats develop
compensatory left ventricular hypertrophy by the age of 11 weeks,
and die from heart failure between 16 to 21 weeks [13,20]. Here
we show that 17 week-old hypertensive Dahl salt-sensitive rats also
exhibit decreased cardiac proteasomal ATP-dependent proteolytic
activity and increased levels of oxidized proteins and soluble
misfolded protein oligomers (Fig. 5B–D). Similar to the effect of
PKCbII inhibition in the myocardial infarction-induced HF model
in rats, sustained treatment with bIIV5-3 (but not the bI inhibitor)
between weeks 11–17, reduced PKCbII activity to basal levels
(Fig. 5A), restored ATP-dependent proteasomal activity and
decreased the levels of misfolded cardiac proteins to those seen
in control animals (Fig. 5B–D). Importantly, bIIV5-3 (but not the
bI inhibitor) treatment prevented the decrease in fractional
shortening in hypertensive rats (Fig. 5E). Further, while treated
with the PKCbII inhibitor (between weeks 11–17), none of the
hypertensive rats died, as compared with 60% death of
hypertensive rats treated with vehicle control or the selective
inhibitor of the alternatively spliced form, bIPKC (Fig. 5F).
Figure 1. Protein quality control disruption and PKCbII activation during progression of heart failure in a post-myocardial
infarction (MI) model of HF in rats. A. MI-induced HF protocol (10 weeks follow up) and example of heart morphology and echo data before (left)
and 4 weeks after myocardial infarction (right) in rats. B. Cardiac fractional shortening, C. Oxidized protein levels, D. Soluble oligomer level and E.
Proteasomal activity during the progression of cardiac dysfunction induced by myocardial infarction. *, p,0.05 compared to week 0 (before surgery).
1,p ,0.05 compared to week 1 after surgery. {,p ,0.05 compared to week 2 after surgery. F. Concordance between fractional shortening and
proteasomal activity, and G. Concordance between accumulation of misfolded cardiac proteins and oxidized proteins at weeks 0, 1, 2, 4 and 10 after
myocardial infarction surgery in rats, H. Cardiac fractional shortening, proteasomal activity, oxidized and misfolded protein levels during the
progression of cardiac dysfunction induced by myocardial infarction. I. The levels of total PKC isozymes (white bars) and translocated active PKCs
(gray bars; Triton-soluble proteins or the particulate fraction/total fraction) at 10 weeks after myocardial infarction relative to control, age-matched
rats (n=6). Total proteins and Triton-soluble proteins of the particulate fraction were normalized against GAPDH and Gao, respectively.
Representative blots are of PKCbII total level and translocation to particulate fraction. All biochemical analyses were performed in the ventricular
remote area. Error bars indicate s.e.m. *, p,0.05 compared to control-TAT. J. PKCbII activity at 10 weeks after myocardial infarction relative to control
age-matched rats (n=3). *, p,0.05 compared to control.
doi:10.1371/journal.pone.0033175.g001
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humans
To determine the extent of PQC disruption in cardiac
remodeling/failure, we used heart biopsies from seven patients
with aortic stenosis-induced left ventricular remodeling who
underwent aortic valve replacement. Heart biopsies from four
patients with ischemic cardiomyopathy-induced HF and from
autopsy specimens of 13 non-failing human hearts as controls were
also examined (Table S1). Despite preserved systolic function, all
patients with aortic stenosis displayed heart failure signs and
symptoms, presenting functional class III–IV of the New York
Heart Association [21]. Both ATP-dependent (26S) and -
independent (20S) proteasomal activities were lower by about
50% in aortic stenosis and ischemic failing hearts as compared
with controls (Fig. 6A) and the levels of oxidized and poly-
ubiquitinated cardiac proteins were two to three-fold higher in
these patients as compared with control subjects (Fig. 6B–C).
There was a negative correlation between proteasomal function
and oxidized cardiac protein accumulation in failing human hearts
(R
2=0.70, p=0.001; Fig. 6D). There is an obvious caveat of using
autopsied hearts as a control. Nevertheless, when we examined
PQC, an ATP-dependent function, we found a better PQC in the
autopsied samples of control subjects relative to the biopsy samples
from remodeled and failing human hearts, suggesting an impaired
PQC in failing human hearts.
Because protein kinase C (PKC) isozymes have been implicated
in HF [11,22] we determined whether specific PKC isozymes play
a role in proteasomal activity and PQC in this disease. Similar to
previous reports [15,23], both aortic stenosis and ischemic failing
human hearts had a five-fold increase in total PKCbII levels, a
two-fold increase in PKCa and no changes in the levels of e and
PKCbI relative to controls (Fig. 6E). Elevated PKCbII and PKCa
protein levels were accompanied by their activation in failing
hearts, as evidenced by their increased association with the cell
particulate fraction (Fig. 6F).
Discussion
In the present study, we showed that human hypertrophied and
failing hearts of different etiologies, as well as myocardial
Figure 2. PKCbII activation inhibits proteasomal activity in vitro and disrupts protein quality control in cultured neonatal
cardiomyocytes. A. Proteolytic activity (upper panel) and phosphorylation of purified proteasome 20S (middle and lower panels) by different
recombinant PKC isozymes (n=3 per group). Purified 20S proteasome (1 ug) was individually incubated with recombinant PKCa, PKCbI, PKCbII or
PKCe (50 ng) at 37uC for 30 minutes. Proteasome phosphorylation was evaluated using serine/threonine phosphorylation antibody (1:1000) and
[c
32P] ATP incorporation. Histone phosphorylation was used to check the effectiveness of different PKC isozymes. Error bars indicate SEM. *, p,0.05
compared to other groups. B. Oxidized protein levels (upper panel) and ATP-dependent proteasomal activity (lower panel) in cultured neonatal
cardiomyocytes. Cells were stimulated with PMA (a non-specific PKC activator) and the effect of PKC isozyme-specific peptide inhibitors (aV5-3, an
aPKC-specific inhibitor; bIV5-3, a bIPKC-specific inhibitor; bIIV5-3, a bIIPKC-specific inhibitor [16]; and eV1-2, an ePKC-specific inhibitor [46]; or
epoxomicin were determined. Error bars indicate SEM. *, p,0.05 compared to control-TAT and bIIV5-3-treated groups. Representative blots of
oxidized proteins and GAPDH. Oxidized proteins were normalized against GAPDH. C. Oxidized protein levels (upper panel) and ATP-dependent
proteasomal activity (lower panel) in cultured neonatal cardiomyocytes. Cultured neonatal cardiomyocytes were PKCb or PKCa down-regulated
(siRNA) plus/minus bIIV5-3 and challenged with phorbol ester (PMA). NC, negative control for siRNA. Representative blots of PKCbII and PKCa showed
siRNA effectiveness. Oxidized proteins were normalized against GAPDH. Error bars indicate SEM. *, p,0.05 compared to control (non-treated cells),
PKCb down-regulated treated cells and PKCa down-regulated treated cells plus bIIV5-3.
doi:10.1371/journal.pone.0033175.g002
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displayed UPS dysfunction-mediated PQC disruption and elevat-
ed PKCbII protein activity. We also demonstrated for the first
time that PKCbII activation resulted in decreased proteasomal
activity and accumulated damaged proteins. Moreover, improved
proteasomal function by sustained inhibition of PKCbII, using the
highly selective PKCbII inhibitor peptide, bIIV5-3 [16], signifi-
cantly improved cardiac PQC, ventricular function and survival of
myocardial infarction- and hypertensive-induced heart failure
models in rats. Of interest, sustained proteasomal inhibition (by
bortezomib treatment) abrogated PKCbII-mediated cardioprotec-
tive effects and resulted in elevated mortality in the myocardial
infarction-induced rat heart failure model. Thus, PKCbII hyper-
activation appears to contribute to UPS dysfunction-mediated
PQC disruption and subsequent decreased cardiomyocyte viabil-
ity, cardiac function and survival in HF (Fig. 7).
UPS-mediated PQC disruption has been involved in several
chronic degenerative diseases, including neurodegenerative dis-
eases, cancer and cardiac ischemia [24,25,26], where UPS
malfunction culminates in accumulation of abnormal protein-
mediated cellular dysfunction and apoptosis. These findings are
extended to human heart failure, since we demonstrate here a
,50% decrease in proteasomal activity and an ,3-fold increase in
both polyubiquitinated and oxidized proteins in human failing
Figure 3. Sustained PKCbII inhibition re-establishes protein quality control and improves cardiac function in myocardial infarction-
induced model of heart failure. A. Schematic panel of PKCbII treatment in the post-MI heart failure model, representative blots of PKCbII total
level and translocation to particulate fraction, and PKCbII activity from left ventricle tissue from 22-week-old myocardial infarction-induced heart
failure (10 wks after MI surgery) TAT-treated, bIIV5-3-treated and control (sham) rats (n=3 per group). B. 20S proteasome subunits (a5/7, b1, b5 and
b7) were precipitated from left ventricle tissue from 22-week-old myocardial infarction-induced heart failure (10 wks after MI surgery) TAT-treated,
bIIV5-3-treated and control (sham) rats (n=3 per group), and then probed with PKCbII, PKCe and anti-serine and threonine phosphorylation
antibodies. Equal sample loading was verified using a5/7, b1, b5 and b7 proteasome subunits antibody. C. ATP-dependent and -independent cardiac
proteasomal activity. D. Representative blots of proteasome 20S, a-b-crystallin, HSP27, caspase-3, cleaved caspase-3 and GAPDH in heart samples
from 22 week-old rats (10 wks after MI surgery) (n=6 per group). Data quantification and statistical details are in supplementary Fig. 4. E. Oxidized
protein levels, F. polyubiquitinated protein levels and G. soluble oligomer accumulation in heart samples from control (sham, white bars), TAT-
treated (gray bars) and bIIV5-3-treated (green bars) heart failure rats as determined by Western blot (E, F) and slot-blot analysis (G). H. Average
fractional shortening data from each group at 16 weeks and 22 weeks. All biochemical analyses were performed in the ventricular remote area. Error
bars indicate SEM. *, p,0.05 compared to control (sham) rats. 1,p ,0.05 compared to bIIV5-3-treated heart failure rats.
doi:10.1371/journal.pone.0033175.g003
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cantly correlated with increased accumulation of oxidized proteins
in the failing human hearts (R
2=0.70, p=0.0001, Fig. 6D). Thus,
cardiac dysfunction, decreased UPS activity and PQC inadequacy
seem to be common phenomena in developing heart failure, and
the progressive PQC disruption paralleled cardiac function decline
after myocardial infarction in rats (Fig. 1). Although the data using
human-derived tissue samples were similar to those we obtained
from the two animal models of HF, there is an inherent variability
in disease type and comorbidity-associated factors. Further caveat
is the use of pathological specimens from subjects who died of
causes other than HF; the cause of death and the timing of sample
collection relative to the time of death may introduce additional
variable and therefore are not optimal controls. Despite these
limitations, the similar findings in humans, in two animal models
and in culture support our conclusion regarding the role of
PKCbII in regulation of proteasomal function in failing hearts.
A number of studies have shown that activation of PKC
contributes to a variety of heart diseases by targeting contractile
myofilaments, mitochondrial proteins and transcriptional factors
[26,27]. Different PKC isozymes have been implicated in HF [10].
Similar to previous findings from failed human hearts [15,23], we
found that both aortic stenosis and ischemic-failing human hearts
presented a significant increase in total PKCbII and PKCa levels
accompanied by their activation. Similarly, we found that of the
PKC isozymes expressed in heart, only PKCbII was activated in
failing hearts from myocardial infarction- and hypertensive-
induced HF rats. Further, we showed that PKCbII isozyme
activation directly regulates proteasomal activity and PQC.
PKCbII (but not aPKC or PKCbI) activation results in
phosphorylation of the purified 20S proteasome in vitro with a
reduction in its activity (Fig. 2A). The functional consequence of
PKCbII-induced 20S proteasome phosphorylation was also
demonstrated in isolated neonatal cardiomyocytes since both
Figure 4. Protein quality control re-establishment by PKCbII inhibition improves survival and cardiac integrity in myocardial
infarction-induced model of heart failure. A. bIIV5-3 improved cardiac integrity in the post-MI-induced HF model in rats. Heart samples were
collected from 22 week-old control (sham), TAT-treated and bIIV5-3-treated heart failure rats (10 wks after MI surgery). Samples from a non-infarcted
area (contractile zone) were processed for electron microscopy analysis. The integrity of cardiac myofibril structure (arrow head) was analyzed in each
group (n=3 per group). N, nucleus; S, sarcomere; SR, sarcoplasmic reticulum; Z, Z disc; M, mitochondria. B. Schematic panel of sustained treatment
with TAT, bIIV5-3, bortezomib or bortezomib plus bIIV5-3 in post-myocardial infarction-induced heart failure in rats. C. bIIV5-3 improved survival of
rats with post-myocardial infarction-induced heart failure. Note that sustained treatment of heart failure rats with a specific proteasome inhibitor
(bortezomib, 0,2 mg/kg, thrice weekly) either alone or combined with bIIV5-3 culminated in 100% mortality as well as abrogated the cardioprotective
effects of bIIV5-3 treatment. Control (sham) rats treated with bortezomib did not present increased mortality. Error bars indicate SEM. *, p,0.05
compared to control (sham) rats. 1,p ,0.05 compared to bIIV5-3-treated heart failure rats. #,p ,0.05 compared to TAT-treated heart failure rats.
doi:10.1371/journal.pone.0033175.g004
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for a, bI or PKCe) and PKCb knockdown using siRNA abrogated
PMA-induced proteasomal dysfunction and the accumulation of
damaged proteins (Fig. 2B–C). Since proteasomal activity is
regulated by multiple factors, such as intracellular ATP levels [26]
and post-translational modification of the proteasome
[28,29,30,31], the in vitro findings might not reflect proteasomal
regulation in vivo. Thus, we next examined whether PKCbII
activation disrupts cardiac PQC related to UPS dysfunction in
myocardial infarction- and hypertensive-induced HF rats. Both
HF animal models displayed accumulated misfolded proteins
associated with proteasomal dysfunction. Indeed, PKCbII, which
is over-activated in these failing rat hearts, co-immunoprecipitated
with the 20S proteasome and was found to have decreased activity
(Fig. 3B). Taken together, in vitro cell culture and in vivo data
identify PKCbII as a key enzyme in down-regulating proteasomal
activity, which resulted in disrupting cardiac PQC and worsening
HF with increased mortality. Considering this scenario, the usage
of selective inhibitors of PKCbII could provide a new pharma-
cological tool against PQC disruption in heart failure.
The use of proteasome inhibitors for therapeutic purposes has
been proposed based on the major role of proteasomes in
degrading intracellular proteins involved in uncontrolled cell
proliferation and growth [32]. In cardiac disease, both beneficial
and detrimental effects were reported for pharmacologically-
induced proteasome inhibition. While most studies on pressure-
overload hypertrophy have shown that systemic proteasome
inhibition prevented or reversed concentric cardiac hypertrophy
with no impact on cardiac function [33,34], cardiotoxic effects
were attributed to proteasome inhibition in normal and ischemic
hearts [26,35,36]. These findings raise important questions
regarding the degree of proteasomal inhibition, which inhibitor
should be used (reversible or irreversible) and the appropriate
therapeutic time window (when and for how long) such an
inhibitor should be used. The latter is of particular interest, since
long-term use of proteasome inhibitors seem counterintuitive
based on UPS dysfunction- mediated PQC disruption reported in
chronic cardiac proteinopathies [37,38] and as reported here in
human HF. Further, the chronic use of the proteasome inhibitor,
bortezomib, for chemotherapy was reported to cause cardiac
complications ranging from cardiotoxicity to HF in some cancer
patients [39]. Relevant to these observations, we found that
sustained bortezomib treatment resulted in 100% mortality in
myocardial infarction-induced HF rats (fractional shortening
below 25%) and blocked PKCbII-related cardioprotective effects.
Since control animals treated with bortezomib did not die, these
findings highlight the contribution of intact UPS function to
cardiac integrity and strengthen our premise that the improve-
ments in heart function/survival induced by PKCbII inhibition is
mediated in part by protecting proteasomal function. It is also
important to emphasize that most HF patients are elderly and that
proteasome activity declines with ageing [40], which might suggest
Figure 5. PKCbII inhibition repairs protein quality control in hypertension-induced heart failure model in rats. A. Schematic panel of
sustained PKCbI, bII or e inhibition in hypertension-induced model of heart failure in rats. Representative blots of PKCbII total level and translocation
to particulate fraction. B. ATP-dependent and -independent cardiac proteasomal activity, C. Oxidized proteins (as determined by Western blot) and
D. cardiac soluble oligomer accumulation (as determined by slot blot) in heart samples from 17 week-old normotensive rats (white bar), TAT-treated
(gray bar), bIV5-3-treated (gray bar), bIIV5-3-treated (green bar) and eV1-2-treated (gray bar) hypertensive rats. E. Average fractional shortening data
from each group at the age of 17 weeks-old. F. bIIV5-3 improved survival of rats with hypertension-induced heart failure. Error bars indicate SEM. *,
p,0.05 compared to control (sham) rats. 1,p ,0.05 compared to bIIV5-3-treated heart failure rats. Data from Fig. b–d were analyzed by one-way
analysis of variance (ANOVA) with post-hoc testing by Tukey. Survival was analyzed by the standard Kaplan-Meier analysis with log-rank test.
doi:10.1371/journal.pone.0033175.g005
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PQC disruption.
Considering that proteasomal dysfunction is likely responsible
for PQC disruption in HF, therapies that prevent or reverse
selectively HF-induced proteasomal dysfunction may be of value
for these patients. Our data in two models of HF in rats suggest
that sustained inhibition of PKCbII may provide such novel
treatment for HF, since selective inhibition of PKCbII with bIIV5-
3 appears safe, even after many weeks of treatment [9,11,17]. We
showed in animal models that inhibition of PKCbII with bIIV5-3
treatment re-established cardiac PQC, and not only prevented
further deterioration of cardiac function, but actually improved
Figure 6. Impaired protein quality control in left ventricular remodeling and heart failure in humans. A. ATP-dependent and -
independent proteasomal activity, B. oxidized protein levels (determined by Western blot) and C. polyubiquitinated protein levels (determined by
Western blot) in biopsied hearts from aortic stenosis-induced left ventricular remodeling (LVR) patients (green bars), ischemic cardiomyopathy-
induced heart failure patients (red bars) and autopsied non-failing human hearts (white bars). D. Negative correlation between proteasomal function
and oxidized protein accumulation in failing (aortic stenosis-LVR and ischemic-HF) and non-failing heart samples. E. Total PKC levels in failing hearts
compared to non-failing hearts and F. Representative blots of PKCbII and PKCa proteins in total and Triton-soluble fraction (particulate fraction) in
biopsied hearts from aortic stenosis-induced left ventricular remodeling patients (n=6, green bars) and ischemic cardiomyopathy-induced heart
failure patients (n=3, red bars) compared to autopsied non-failing human hearts (n=6, trace). Total and Triton-soluble fractions were normalized
against GAPDH and Gao, respectively. Error bars indicate SEM. *, p,0.05 compared to control (non-failing heart). 1,p ,0.05 compared to aortic
stenosis-LVR patients.
doi:10.1371/journal.pone.0033175.g006
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rat models of HF with etiologies most common to HF in humans
(Fig. 4C and 5F). These results support a model in which the
actions of PKCbII in hypertrophied and failing hearts involve
primarily the inactivation of the proteasome. Further studies
investigating both direct and indirect proteasomal regulation by
PKCbII during heart failure progression are required. However,
we cannot exclude the possibility that PKCbII exerts other effects
that contribute to this pathology. Also, the contribution of other
proteolytic systems such as autophagic/lysosomal pathways to
cardiac protein quality control in HF should be considered.
Taken together, our data suggest that PKCbII-mediated
impairment of cardiac PQC may be critical, at least in part, for
the development of cardiac dysfunction in failing hearts. In
addition, re-establishment of proteasomal function and PQC with
bIIV5-3 treatment suggests specific PKCbII inhibition may be a
valuable therapeutic approach for patients with HF.
Methods
Ethics statement
The animal protocols were approved by the Stanford University
Institutional Animal Care and Use Committee (Protocol ID:
14746) and by the Ethical Committee of the School of Physical
Education and Sport of the University of Sa ˜o Paulo, Brazil
(Protocol ID: 2009/13). Human biopsies were taken according to
the procedure approved by the Human Ethical Committee in
Brazil (Protocol ID: CAPP2409/04/029) and USA (IRB number:
350, protocol ID: 96726). Written informed consent was also
obtained from all patients undergoing aortic valve replacement
surgery.
Myocardial infarction-induced heart failure model
Myocardial infarction was induced by ligation of the left
anterior descending coronary artery (LAD) in Wistar normoten-
sive rats at 12 weeks of age, as described [41]. After the LAD
surgery, animals were followed up to 10 weeks to establish the time
window of proteasome activity and protein quality control. In
addition, to determine the effect of sustained PKCbII inhibition on
PQC during heart failure, another group of animals with
fractional shortening ,25% (MI-HF) was treated between the
ages of 16 and 22 weeks with TAT47–57-bIIV5-3 (3 mg/kg/day) or
with equimolar concentration of TAT47–57-carrier peptide, using
Alzet osmotic pumps, which were replaced every two weeks. The
sham-infarcted group was subjected to TAT treatment as a
negative control. Echocardiography (Acuson Sequoia, 14-MHz) to
evaluate fractional shortening was performed 10 weeks after LAD
surgery as well as before and after sustained PKCbII inhibition. In
addition, MI-HF rats were treated between the ages of 16 and 22
weeks with a specific proteasome inhibitor (bortezomib, 0.2 mg/
kg, thrice weekly) either alone or together with bIIV5-3. The
bortezomib dose was previously shown to produce blood
concentrations of bortezomib comparable with those seen in
humans [36,42]. All the biochemical analyses were performed in
the ventricular remote area.
Hypertension-induced model of heart failure
Male Dahl rats were fed with an 8% NaCl-containing diet (high
salt diet) or with a 0.3% NaCl low salt diet from the age of 6 weeks
onward, as described [13]. All peptides were delivered using
osmotic pumps implanted subcutaneously and replaced every two
weeks, Dahl rats were treated between the ages of 11 and 17 weeks
with the selective PKCbI inhibitor peptide, TAT47–57-bIV5-3
(3 mg/kg/day); the selective PKCbII inhibitor peptide, TAT47–57-
bIIV5-3 (3 mg/kg/day); the selective PKCe inhibitor peptide,
TAT47–57-eV1-2 (3 mg/kg/day); or an equimolar concentration
of TAT47–57 carrier peptide alone (1.6 mg/kg/day), as a control.
Cell culture
Cardiac myocytes were isolated from 1-day-old Sprague-
Dawley rat litters, as described [43]. Short interfering RNA was
transfected into cardiac myocytes as described [43].
Proteasome phosphorylation assay
1 ug of purified 20S proteasome (PW8720, Enzo Lif Sci, PA)
was incubated with 50 ng of recombinant PKCa, PKCbI,
PKCbII or PKCe (Cell Signaling, MA) in assay buffer (25 mM
Tris-HCl, pH 7.5, 1 mM CaCl2, 20 mM MgCl2, 1 mM DTT,
25 nM ATP) at 37uC for 30 minutes. Proteasome phosphorylation
was evaluated using serine/threonine phosphorylation antibody
(1:1000) and [c
32P] ATP incorporation, as described [44]. Histone
phosphorylation was used to check the effectiveness of different
PKC isozymes.
Kinase assay
The kinase assay was performed as described [44].
Proteasome activity
ATP-dependent (26S) and -independent (20S) chymotrypsin-
like activity of the proteasome was assayed in the total lysate from
heart or isolated cardiomyocyte using the fluorogenic peptide Suc-
Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (LLVY-AMC,
Figure 7. Scheme depicting a possible mechanism of PKCbII-
mediated PQC disruption during heart failure establishment.
doi:10.1371/journal.pone.0033175.g007
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Inc, CA), in Tris-HCl buffer (25 mmol/L, pH 7.5). Kinetic
analyses were carried out using 50 mg of protein for 30 min at
37uC in the absence and presence of 25 mmol/L ATP plus
5.0 mmol/L MgCl2, with the difference attributed to ATP-
dependent proteasomal activity. Excitation/emission wavelengths
were 350/440 nm. Data were normalized by proteasomal activity
in the presence of 2 mmol/L of epoxomicin (a selective proteasome
inhibitor). The purified 20S proteasome activity (Fig. 2A) was
carried out after finishing the in vitro proteasome phosphorylation
assay (see method for proteasome phosphorylation assay).
Cellular oxidized proteins
Protein oxidation was determined as previously described [45].
We evaluated oxidatively modified proteins using an Oxyblot kit
(S7150, Millipore, MA). Samples were normalized by GAPDH
and expressed as percent control.
Statistics
Data are expressed as mean 6 s.e.m. One-way analysis of
variance (ANOVA) with post-hoc testing by Tukey was used to
analyze data from Fig. 1b–e,i, 2a–c, 3a,c,e–g, 5b–e and 6a–c,e.
Two-way repeated measures analysis of variance (ANOVA) with
post-hoc testing by Tukey was used to analyze data from Fig. 3h.
Student’s t-test (one-tailed distribution/two-sample equal variance)
was used to analyze data from Fig. 1j and 3e. Linear regression
analysis and correlation test by Pearson’s method were used to
assess concordance of Fig. 1f,g and 6d. Survival was analyzed by
the standard Kaplan-Meier analysis with log-rank test. A value of
P,0.05 was considered significant.
Reagents, peptide synthesis, electron microscopy, tissue
fractionation, immunoprecipitation, immunoblot assays
and human samples
Detailed methods can be found in the Supporting Information
S1.
Supporting Information
Figure S1 PKCbII inhibition improved ATP-dependent
proteasomal activity and decreased hydrogen peroxide-
induced accumulation of oxidized proteins and cell
death in cultured neonatal cardiomyocytes. a. Schematic
panel of PKCbII inhibition and hydrogen peroxide challenge in
cultured neonatal cardiomyocytes. b. Cultured neonatal cardio-
myocytes were pre-treated with TAT or bIIV5-3 plus/minus
epoxomicin and challenged with hydrogen peroxide for 5 min.
Proteasomal activity, oxidized proteins accumulation and cell
death were evaluated after 24 hrs. Cell death was evaluated by
lactate dehydrogenase (LDH) release assay in the medium after
24 hrs. Epoxomicin abrogated the bIIV5-3 cytoprotective effect.
Error bars indicate SEM. *, p,0.05 compared to control (non-
treated cells). 1,p ,0.05 compared to bIIV5-3-treated cells. Data
were analyzed by one-way analysis of variance (ANOVA) with
post-hoc testing by Tukey.
(DOC)
Figure S2 Sustained treatment with bIIV5-3 decreased
PKCbII translocation to active fraction in myocardial
infarction-induced heart failure rats. The ratio of translo-
cation of PKC to active fraction (Triton-soluble proteins or the
particulate fraction/total fraction) in 22-week old rats (10 wks after
MI surgery) (n=6 per group). Total and Triton-soluble fractions
were normalized against GAPDH and Gao, respectively. Error
bars indicate SEM. *, p,0.05 compared to control (sham rats,
trace). 1,p ,0.05 compared to bIIV5-3-treated heart failure rats.
Total PKC levels and translocations were analyzed by one-way
analysis of variance (ANOVA) with post-hoc testing by Tukey.
(DOC)
Figure S3 Sustained bIIV5-3 treatment decreased a-b-
crystallin, HSP27, cleaved caspase-3, p53 and IkB
protein levels in myocardial infarction-induced heart
failure. a. Representative blots of 20S proteasome subunits (a5/
7, b1, b5 and b7), a-b-crystallin, HSP27, caspase-3, cleaved
caspase-3, p53, IkB and GAPDH protein levels in heart samples
from 22 week-old rats (10 wks after MI surgery) (n=6 per group).
b. Cardiac proteasome 20S proteasome subunits (a5/7, b1, b5
and b7), c. a-b-crystallin, d. HSP27, e. HSP 90, f. Ratio of
cardiac cleaved caspase-3/caspase-3, g. p53 and h. IkB were
measured in left ventricle tissue from 22 week-old myocardial
infarction-induced heart failure (10 wks after MI surgery) TAT-
treated (gray bar), bIIV5-3-treated (green bar) and control (sham,
white bar) rats. Data were normalized against GAPDH. Error bars
indicate SEM. *, p,0.05 compared to control (sham). 1,p ,0.05
compared to bIIV5-3-treated heart failure rats. Data were
analyzed by one-way analysis of variance (ANOVA) with post-hoc
testing by Tukey.
(DOC)
Table S1 Individual characteristics of left ventricular
remodeling and heart failure patients.
(DOC)
Supporting Information S1 Reagents, peptide synthesis,
electron microscopy, tissue fractionation, immunoprecipitation,
immunoblot assays and human samples.
(DOC)
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